Illumina Inc. (ILMN) Director Sells $1,500,000.00 in Stock

Illumina Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $150.00, for a total value of $1,500,000.00. Following the completion of the sale, the director now owns 498,061 shares of the company’s stock, valued at approximately $74,709,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

A number of brokerages have weighed in on ILMN. Mizuho reiterated a “neutral” rating and issued a $150.00 price objective on shares of Illumina in a research note on Tuesday, April 19th. Barclays PLC cut their price target on Illumina from $175.00 to $160.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 19th. Zacks Investment Research upgraded Illumina from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. Piper Jaffray Cos. restated an “overweight” rating and set a $161.00 price target on shares of Illumina in a research note on Friday, July 15th. Finally, Bank of America Corp. cut Illumina from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 19th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $163.61.

Illumina Inc. (NASDAQ:ILMN) traded up 2.57% during trading on Thursday, reaching $166.42. The company had a trading volume of 1,501,704 shares. The stock has a 50 day moving average price of $144.02 and a 200 day moving average price of $150.19. The firm has a market capitalization of $24.43 billion and a price-to-earnings ratio of 56.99. Illumina Inc. has a 12 month low of $127.10 and a 12 month high of $220.86.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.13. During the same period in the previous year, the firm earned $0.80 EPS. The business had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. The firm’s revenue was up 11.3% on a year-over-year basis. On average, equities research analysts predict that Illumina Inc. will post $3.50 earnings per share for the current year.

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.